RxDoctor Payments Data

Charles Jennisch

Psychiatry · Urbandale, IANPI 1225133606

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $716,239 of the $948,571 with a category attached, or 75.5%. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 49.8% of the total. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$948,571in general payments, 2019–2025

Across 1,273 payments — averaging $745.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$472K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150K
  • Axsome Therapeutics, Inc.$134K
  • Neurocrine Biosciences, Inc.$68K
  • E.r. Squibb & Sons, L.L.C.$47K
  • Takeda Pharmaceuticals U.S.A., Inc.$40K
  • plus $37K from 15 others

What the payments were for

  • Consulting fees$151,61116%
  • Speaking & faculty fees$716,23976%
  • Travel & lodging$62,8917%
  • Food & beverage$17,6842%
  • Education$1460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$948,571 in reported general payments places this provider in the 95th percentile of 245 psychiatry providers in Iowa.

See all psychiatry providers in Iowa

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZyprexaOlanzapine21$22,337
CaplytaLumateperone Tosylate13$21,663
AuvelityDextromethorphan Hbr/Bupropion15$18,183
TrintellixVortioxetine Hydrobromide19$17,792
Bupropion XlBupropion Hcl81$3,210
Vilazodone Hcl21$2,977
Venlafaxine Hcl ErVenlafaxine Hcl100$2,436
Clozapine27$2,001
Duloxetine Hcl54$1,618
Quetiapine Fumarate89$1,602
Buspirone Hcl57$1,450
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$1,268
Clonazepam97$1,189
Mirtazapine40$686
Methylphenidate Hcl15$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$149,884$21,66313 claims
Axsome Therapeutics, Inc.Auvelity$134,134$18,18315 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$40,066$17,79219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 245 psychiatry providers in Iowa.

Other psychiatry in Urbandale

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →